| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015 | 1094 | 2015 |
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 945 | 2016 |
| Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013 | 693 | 2013 |
| The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015 | 456 | 2015 |
| Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ... Gut 67 (11), 1995-2005, 2018 | 213 | 2018 |
| Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ... Cancer Cell 34 (1), 148-162. e7, 2018 | 136 | 2018 |
| Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ... Annals of oncology 26 (9), 1994-1999, 2015 | 129 | 2015 |
| Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ... Clinical cancer research 19 (8), 2265-2272, 2013 | 121 | 2013 |
| Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer D Oddo, EM Sennott, L Barault, E Valtorta, S Arena, A Cassingena, ... Cancer research 76 (15), 4504-4515, 2016 | 115 | 2016 |
| Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer C Moutinho, A Martinez-Cardús, C Santos, V Navarro-Pérez, ... Journal of the national cancer institute 106 (1), djt322, 2014 | 108 | 2014 |
| A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin S Arena, G Corti, E Durinikova, M Montone, NM Reilly, M Russo, ... Clinical Cancer Research 26 (6), 1372-1384, 2020 | 74 | 2020 |
| Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer F Tosi, A Sartore-Bianchi, S Lonardi, A Amatu, F Leone, S Ghezzi, ... Clinical colorectal cancer 19 (4), 256-262. e2, 2020 | 69 | 2020 |
| Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers T Fujii, A Barzi, A Sartore-Bianchi, A Cassingena, G Siravegna, DD Karp, ... Clinical Cancer Research 23 (14), 3657-3666, 2017 | 66 | 2017 |
| Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients G Crisafulli, A Sartore-Bianchi, L Lazzari, F Pietrantonio, A Amatu, ... Cancer Discovery 12 (7), 1656-1675, 2022 | 56 | 2022 |
| Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ G Della Chiara, F Gervasoni, M Fakiola, C Godano, C D’Oria, L Azzolin, ... Nature communications 12 (1), 2340, 2021 | 54 | 2021 |
| Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer L Lazzari, G Corti, G Picco, C Isella, M Montone, P Arcella, E Durinikova, ... Clinical Cancer Research 25 (20), 6243-6259, 2019 | 52 | 2019 |
| Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013; 3: 658–673. doi: 10.1158/2159-8290 A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... CD-12-0558.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 50 | |
| Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, C Funaioli, ... Cancer treatment reviews 36, S1-S5, 2010 | 46 | 2010 |
| Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer A Amatu, L Barault, C Moutinho, A Cassingena, K Bencardino, S Ghezzi, ... Annals of Oncology 27 (6), 1062-1067, 2016 | 39 | 2016 |
| Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor G Siravegna, A Sartore-Bianchi, B Mussolin, A Cassingena, A Amatu, ... Annals of Oncology 28 (6), 1302-1308, 2017 | 38 | 2017 |
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyZweryfikowany adres z ospedaleniguarda.it
